Associated Papers
Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.
Vahdat-Lasemi F et al.
Atherosclerosis, 2025
Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study.
Gagnon E et al.
Circulation. Genomic and Precision Medicine, 2025
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization.
Xu D et al.
Atherosclerosis, 2025
Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations.
Koyama S et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Instrumental variable and colocalization analyses identify endotrophin and HTRA1 as potential therapeutic targets for coronary artery disease.
Lee PC et al.
Iscience, 2024
Elevated plasma triglycerides increase the risk of psoriasis: a cohort and Mendelian randomization study.
Greve AM et al.
The British Journal of Dermatology, 2024
Impact of loss-of-function in angiopoietin-like 4 on the human phenome.
Gagnon E et al.
Atherosclerosis, 2024
Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk.
Landfors F et al.
European Heart Journal Open, 2024
Association of a genetic variant in angiopoietin-like 3 with serum HDL-C and risk of cardiovascular disease: A study of the MASHAD cohort over 6 years.
Aghasizadeh M et al.
Molecular Genetics & Genomic Medicine, 2024
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
Larouche M et al.
Current Atherosclerosis Reports, 2023
Elucidation of Increased Cervical Cancer Risk Due to Polymorphisms in XRCC1 (R399Q and R194W), ERCC5 (D1104H), and NQO1 (P187S).
Das AP et al.
Reproductive Sciences (thousand Oaks, Calif.), 2023
Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.
Landfors F et al.
Journal of Lipid Research, 2023
Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.
Sosnowska B et al.
Journal of Clinical Medicine, 2022
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants.
Aragam KG et al.
Nature Genetics, 2022
Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.
Taghizadeh E et al.
Biochemical Genetics, 2022
Genetics and regulation of HDL metabolism.
Kardassis D et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 2022
Common and Rare 5'UTR Variants Altering Upstream Open Reading Frames in Cardiovascular Genomics.
Soukarieh O et al.
Frontiers in Cardiovascular Medicine, 2022
Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices.
Natarajan P et al.
Nature Communications, 2021
Cross-talk between ANGPTL4 gene SNP Rs1044250 and weight management is a risk factor of metabolic syndrome.
Tong Z et al.
Journal of Translational Medicine, 2021
Quantile-Dependent Expressivity and Gene-Lifestyle Interactions Involving High-Density Lipoprotein Cholesterol.
Williams PT
Lifestyle Genomics, 2021
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease.
Nielsen JB et al.
Nature Communications, 2020
Association of a genetic variant in the angiopoietin-like protein 4 gene with cervical cancer.
Rahmani F et al.
Pathology, Research and Practice, 2020
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study.
Kaltoft M et al.
European Heart Journal, 2020
The influence of rare variants in circulating metabolic biomarkers.
Riveros-Mckay F et al.
Plos Genetics, 2020
Association of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome.
Kharazmi-Khorassani S et al.
Bmc Medical Genetics, 2019
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution.
Justice AE et al.
Nature Genetics, 2019
ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in participants with obesity.
Bailetti D et al.
Obesity Science & Practice, 2019
Rare BANF1 Alleles and Relatively Frequent EMD Alleles Including 'Healthy Lipid' Emerin p.D149H in the ExAC Cohort.
Dharmaraj T et al.
Frontiers in Cell and Developmental Biology, 2019
Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program.
Klarin D et al.
Nature Genetics, 2018
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Lotta LA et al.
Jama Cardiology, 2018
A subregion-based burden test for simultaneous identification of susceptibility loci and subregions within.
Zhu B et al.
Genetic Epidemiology, 2018
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals.
Natarajan P et al.
Nature Communications, 2018
Genomic insights into the causes of type 2 diabetes.
Langenberg C et al.
Lancet (london, England), 2018
Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes.
Gusarova V et al.
Nature Communications, 2018